HIGHLIGHTS
- who: Ganesan Ramamoorthi et al. from the Tampa, Florida, USA Laboratory Medicine, University have published the research: Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma, in the Journal: (JOURNAL)
- what: WHAT THIS STUDY ADDS u21d2 This study shows that intratumoral delivery (i.t.) of HER2 peptide-u00adpulsed type 1 polarized dendritic cell (HER2-u00ad DC1) plus anti-u00ad HER2 antibodies was more effective than standard chemotherapy combined with anti-u00adHER2 antibodies and generated robust systemic antitumor immunity and causing regression of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.